We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





ECCMID 2022 Takes Place for the First Time as Hybrid Event Both Onsite and Online

By LabMedica International staff writers
Posted on 22 Apr 2022

The 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022) took place in Lisbon, Portugal from April 23-26 – for the first time as a hybrid event both onsite and online. More...

ECCMID is the world’s premier clinical microbiology & infectious diseases event organized by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) that brings together experts from many fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues. This year, the congress featured a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted program.

ECCMID 2022 offered excellent opportunities to corporate partners to showcase their latest findings, share their experiences and knowledge and demonstrate practical techniques and guidance. A comprehensive program covered the entire range of ECCMID topics with high-level speakers. Participants had the opportunity to meet researchers from many parts of the world to discuss methods, results and the impact on clinical and laboratory practice. Additionally, young professionals had the opportunity to discuss their ideas and projects with renowned experts in a variety of interactive sessions that also provided networking opportunities.

This year’s ECCMID once again featured pipeline corners where innovative companies and research groups were offered a platform to present their early-stage antimicrobial therapies, diagnostic products in development, and research funding opportunities to a wider audience. This was complemented by scientific content co-developed with the industry such as the integrated symposia.

Other new features from ECCMID 2021 that returned this year were the Keynote Fireplace sessions where ECCMID keynote speakers met with a small group of participants to enter a more in-depth discussion on their keynote lecture. Additionally, the infectious disease-themed Escape Room was reprised and updated as an immersive interactive addition.

Related Links:
ESCMID 


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Gold Member
Hematology System
Medonic M16C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.